Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Cardiol Therapeutics (CRDL) Competitors

Cardiol Therapeutics logo
C$1.85 +0.03 (+1.65%)
As of 04:00 PM Eastern
Compare

CRDL vs. TEV, NOT, PYR, NVO, and DNA

Should you buy Cardiol Therapeutics stock or one of its competitors? MarketBeat compares Cardiol Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiol Therapeutics include Tervita (TEV), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), and Dalradian Resources (DNA). These companies are all part of the "pharmaceutical products" industry.

How does Cardiol Therapeutics compare to Tervita?

Tervita (TSE:TEV) and Cardiol Therapeutics (TSE:CRDL) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Tervita's average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company Overall Sentiment
Tervita Neutral
Cardiol Therapeutics Neutral

Tervita has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tervita, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TervitaC$1.36B0.00-C$1.04M-C$0.01N/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.39N/A

Tervita's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TervitaN/A N/A N/A
Cardiol Therapeutics N/A -229.16%-54.15%

0.1% of Cardiol Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Tervita beats Cardiol Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Noront Resources?

Cardiol Therapeutics (TSE:CRDL) and Noront Resources (CVE:NOT) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Noront Resources is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.39N/A
Noront ResourcesN/AN/AN/A-C$0.15N/A

0.1% of Cardiol Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.00 equaled Noront Resources'average media sentiment score.

Company Overall Sentiment
Cardiol Therapeutics Neutral
Noront Resources Neutral

Noront Resources' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -229.16% -54.15%
Noront Resources N/A N/A N/A

Summary

Cardiol Therapeutics and Noront Resources tied by winning 3 of the 6 factors compared between the two stocks.

How does Cardiol Therapeutics compare to PyroGenesis Canada Inc. (PYR.V)?

PyroGenesis Canada Inc. (PYR.V) (CVE:PYR) and Cardiol Therapeutics (TSE:CRDL) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

0.1% of Cardiol Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PyroGenesis Canada Inc. (PYR.V) has higher revenue and earnings than Cardiol Therapeutics. PyroGenesis Canada Inc. (PYR.V) is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PyroGenesis Canada Inc. (PYR.V)C$6.01M100.97-C$3.94M-C$0.03N/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.39N/A

In the previous week, PyroGenesis Canada Inc. (PYR.V) had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 1 mentions for PyroGenesis Canada Inc. (PYR.V) and 0 mentions for Cardiol Therapeutics. PyroGenesis Canada Inc. (PYR.V)'s average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company Overall Sentiment
PyroGenesis Canada Inc. (PYR.V) Neutral
Cardiol Therapeutics Neutral

PyroGenesis Canada Inc. (PYR.V)'s return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PyroGenesis Canada Inc. (PYR.V)N/A N/A N/A
Cardiol Therapeutics N/A -229.16%-54.15%

Summary

PyroGenesis Canada Inc. (PYR.V) beats Cardiol Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Novo Resources Corp. (NVO.V)?

Cardiol Therapeutics (TSE:CRDL) and Novo Resources Corp. (NVO.V) (CVE:NVO) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Novo Resources Corp. (NVO.V) had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 1 mentions for Novo Resources Corp. (NVO.V) and 0 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.00 equaled Novo Resources Corp. (NVO.V)'saverage media sentiment score.

Company Overall Sentiment
Cardiol Therapeutics Neutral
Novo Resources Corp. (NVO.V) Neutral

0.1% of Cardiol Therapeutics shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Novo Resources Corp. (NVO.V)'s return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -229.16% -54.15%
Novo Resources Corp. (NVO.V) N/A N/A N/A

Novo Resources Corp. (NVO.V) is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.39N/A
Novo Resources Corp. (NVO.V)N/AN/AN/A-C$0.11N/A

Summary

Novo Resources Corp. (NVO.V) beats Cardiol Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Dalradian Resources?

Cardiol Therapeutics (TSE:CRDL) and Dalradian Resources (TSE:DNA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Dalradian Resources' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -229.16% -54.15%
Dalradian Resources N/A N/A N/A

0.1% of Cardiol Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Dalradian Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.39N/A
Dalradian ResourcesN/AN/AN/A-C$0.03N/A

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.00 equaled Dalradian Resources'average media sentiment score.

Company Overall Sentiment
Cardiol Therapeutics Neutral
Dalradian Resources Neutral

Summary

Cardiol Therapeutics and Dalradian Resources tied by winning 3 of the 6 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRDL vs. The Competition

Export
MetricCardiol TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$213.25MC$2.22BC$6.45BC$12.16B
Dividend YieldN/A2.95%2.76%6.20%
P/E Ratio-4.745.1621.2237.64
Price / SalesN/A1,770.59553.9211.68
Price / Cash0.9810.1843.4982.29
Price / Book8.3310.6110.374.50
Net Income-C$42.93MC$20.70BC$3.57BC$299.09M
7 Day Performance2.21%5.88%6.01%1.38%
1 Month Performance-2.12%3.71%3.52%1.46%
1 Year Performance21.71%23.05%34.13%55.45%

Cardiol Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRDL
Cardiol Therapeutics
N/AC$1.85
+1.6%		N/A+19.7%C$213.25MN/AN/A20
TEV
Tervita
N/AN/AN/AN/AC$672.00MC$1.36BN/A36,800
NOT
Noront Resources
N/AC$1.10
-0.5%		N/A+0.0%C$612.18MN/AN/A101,700
PYR
PyroGenesis Canada Inc. (PYR.V)
N/AC$3.85
+11.0%		N/A+0.0%C$606.96MC$6.01MN/A90
NVO
Novo Resources Corp. (NVO.V)
N/AC$2.38
-0.4%		N/A+0.0%C$548.24MN/AN/A54,400

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:CRDL) was last updated on 5/25/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel